RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000071.xml
PDF herunterladen
Semin Neurol 2024; 44(04): 414-418
DOI: 10.1055/s-0044-1787551
DOI: 10.1055/s-0044-1787551
Preface
Neurological Aspects of Substance Use Disorder: An Introduction
Authors
As human beings, our greatness lies not so much in being able to remake the world… as in being able to remake ourselves. – Mahatma Gandhi
Publikationsverlauf
Artikel online veröffentlicht:
16. Juli 2024
© 2024. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 NCHS Data Brief, No. 491, March. 2024 , Hyattsville, MD: National Center for Health Statistics
- 2 Center for Behavioral Health Statistics and Quality. 2018 ). 2017 National Survey on Drug Use and Health: Detailed Tables. Accessed May 21, 2024 at: https://www.cdc.gov/nchs/data/databriefs/db491.pdf
- 3 Centers for Disease Control and Prevention. Accessed May 21, 2024 at: https://www.cdc.gov/nchs/data/databriefs/db491.pdf
- 4 O'Donnell J, Tanz LJ, Miller KD. et al. Drug overdose deaths with evidence of counterfeit pill use - United States, July 2019-December 2021. MMWR Morb Mortal Wkly Rep 2023; 72 (35) 949-956
- 5 Marcu J. The legalization of cannabinoid products and standardizing cannabis-drug development in the United States: a brief report. Dialogues Clin Neurosci 2020; 22 (03) 289-293
- 6 Jacobus J, Courtney KE, Hodgdon EA, Baca R. Cannabis and the developing brain: What does the evidence say?. Birth Defects Res 2019; 111 (17) 1302-1307
- 7 CDC Morbidity and Mortality Weekly Report. . Accessed May 21, 2024 at: https://search.cdc.gov/search/?query=xylazine&dpage=1
- 8 McKendrick G, Stull SW, Sharma A, Dunn KE. Availability and Opportunities for Expansion of Buprenorphine for the Treatment of Opioid Use Disorder. . Semin Neurol 2024 (ahead of publication)
- 9 Nguyen T, Ziedan E, Simon K. et al Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic. JAMA Netw Open 2022; 5 (06) e2214765
- 10 Klausen MK, Thomsen M, Wortwein G, Fink-Jensen A. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol 2022; 179 (04) 625-641
- 11 Mahoney III JJ, Hanlon CA, Marshalek PJ, Rezai AR, Krinke L. Transcranial magnetic stimulation, deep brain stimulation, and other forms of neuromodulation for substance use disorders: review of modalities and implications for treatment. J Neurol Sci 2020; 418: 117149
- 12 Substance Use Disorder Treatment | AMA. Accessed May 21, 2024 at: ama-assn.org
- 13 Deak JD, Johnson EC. Genetics of substance use disorders: a review. Psychol Med 2021; 51 (13) 2189-2200 Erratum in: Psychol Med. 2022 Mar 02;1